Teleflex Incorporated (NYSE:TFX) insider Thomas E. Powell sold 5,200 shares of Teleflex stock in a transaction that occurred on Friday, November 23rd. The stock was sold at an average price of $254.10, for a total value of $1,321,320.00. Following the transaction, the insider now owns 15,351 shares of the company’s stock, valued at $3,900,689.10. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
TFX traded up $0.21 during trading on Monday, hitting $275.63. The stock had a trading volume of 234,100 shares, compared to its average volume of 305,826. The company has a market capitalization of $12.66 billion, a PE ratio of 32.79, a price-to-earnings-growth ratio of 2.22 and a beta of 1.13. The company has a debt-to-equity ratio of 0.83, a current ratio of 2.26 and a quick ratio of 1.51. Teleflex Incorporated has a one year low of $227.52 and a one year high of $288.78.
Teleflex (NYSE:TFX) last released its earnings results on Thursday, November 1st. The medical technology company reported $2.52 earnings per share for the quarter, beating analysts’ consensus estimates of $2.41 by $0.11. The firm had revenue of $609.70 million during the quarter, compared to the consensus estimate of $609.05 million. Teleflex had a return on equity of 18.04% and a net margin of 2.81%. The company’s revenue was up 14.0% compared to the same quarter last year. During the same period in the prior year, the company posted $2.12 EPS. Equities analysts anticipate that Teleflex Incorporated will post 9.91 earnings per share for the current fiscal year.
Large investors have recently added to or reduced their stakes in the company. Parallel Advisors LLC lifted its position in shares of Teleflex by 200.0% during the 2nd quarter. Parallel Advisors LLC now owns 450 shares of the medical technology company’s stock valued at $120,000 after acquiring an additional 300 shares during the period. First Hawaiian Bank bought a new stake in shares of Teleflex during the 3rd quarter valued at $156,000. Qube Research & Technologies Ltd bought a new stake in shares of Teleflex during the 2nd quarter valued at $168,000. First Light Asset Management LLC bought a new stake in shares of Teleflex during the 2nd quarter valued at $210,000. Finally, Beaton Management Co. Inc. bought a new stake in shares of Teleflex during the 3rd quarter valued at $213,000. Hedge funds and other institutional investors own 92.42% of the company’s stock.
TFX has been the subject of several recent research reports. TheStreet upgraded Teleflex from a “c+” rating to a “b-” rating in a research note on Wednesday, November 28th. UBS Group initiated coverage on Teleflex in a research note on Tuesday, November 27th. They issued a “buy” rating and a $310.00 price target for the company. ValuEngine upgraded Teleflex from a “hold” rating to a “buy” rating in a research note on Thursday, September 13th. Needham & Company LLC restated a “buy” rating and issued a $315.00 price target on shares of Teleflex in a research note on Friday, November 2nd. Finally, Barclays initiated coverage on Teleflex in a research note on Monday, October 15th. They issued an “equal weight” rating and a $266.00 price target for the company. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Teleflex presently has a consensus rating of “Buy” and a consensus price target of $291.67.
WARNING: This piece was originally reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.baseballdailydigest.com/news/2018/12/03/thomas-e-powell-sells-5200-shares-of-teleflex-incorporated-tfx-stock-2.html.
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.
Featured Article: No Load Funds
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.